Back to top

Zacks.com Most Recent Articles

Zacks Equity Research

Robust Trading, IB Fee Growth to Support Morgan Stanley's Q1 Earnings

Analyst Blog

MS to report Q1 earnings on April 15. Wall Street expects $19.62B revenues, EPS $3.08, with advisory fees +52% on trading and IB strength.

GSNegative Net Change JPMPositive Net Change MSPositive Net Change

Zacks Equity Research

electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?

Tale of the Tape

electroCore (ECOR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ECORPositive Net Change FDMTNegative Net Change

Zacks Equity Research

Wall Street Analysts Think First American Financial (FAF) Could Surge 28.15%: Read This Before Placing a Bet

Tale of the Tape

The mean of analysts' price targets for First American Financial (FAF) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

FAFPositive Net Change

Zacks Equity Research

How Much Upside is Left in Hawkins (HWKN)? Wall Street Analysts Think 27.26%

Tale of the Tape

The average of price targets set by Wall Street analysts indicates a potential upside of 27.3% in Hawkins (HWKN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

HWKNPositive Net Change

Zacks Equity Research

Does Extreme Networks (EXTR) Have the Potential to Rally 32.39% as Wall Street Analysts Expect?

Tale of the Tape

The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Extreme Networks (EXTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

EXTRPositive Net Change

Zacks Equity Research

How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%

Tale of the Tape

The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in DAMORA THERAPEU (DMRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

DMRAPositive Net Change

Zacks Equity Research

Wall Street Analysts See a 32.81% Upside in FTAI Aviation (FTAI): Can the Stock Really Move This High?

Tale of the Tape

The consensus price target hints at a 32.8% upside potential for FTAI Aviation (FTAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

FTAINegative Net Change

Zacks Equity Research

Does SM Energy (SM) Have the Potential to Rally 27.89% as Wall Street Analysts Expect?

Tale of the Tape

The average of price targets set by Wall Street analysts indicates a potential upside of 27.9% in SM Energy (SM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SMNegative Net Change

Zacks Equity Research

Wall Street Analysts See a 46.16% Upside in Nvidia (NVDA): Can the Stock Really Move This High?

Tale of the Tape

The consensus price target hints at a 46.2% upside potential for Nvidia (NVDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

NVDAPositive Net Change

Zacks Equity Research

Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?

Tale of the Tape

The average of price targets set by Wall Street analysts indicates a potential upside of 85.8% in Nurix Therapeutics (NRIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

NRIXPositive Net Change